Co-founder of SyMap Medical Ltd., China
Co-founder of SyMap Medical Ltd., China
Jie Wang, MD, PhD
Dr. Wang is an established and a well known expert in cardiovascular research and the industry. He was the pioneer to introduce biotechnology and biopharmaceuticals into China, funded and led three companies in China to manufacture recombinant protein drugs and interventional cardiology devices, respectively. Dr. Wang has served as a consultant to a number of the world’s largest pharmaceutical companies, venture capital firms, start-up companies and consulting firms. He guided key animal experiments and first-in-human studies in China to prove the concept of Ardian’s renal denervation therapy for hypertension, heart failure and other cardiovascular diseases. He has been awarded “CRT 2012 Best Innovation Award” due to his patents of renal sympathetic nerve mapping/ablation devices. His leadership in both academia and industry has been demonstrated by his extraordinary carrier path: an associate professor at Columbia University, the Dean of Medical School of Nanjing University, Associate Director of the Skirball Center for Cardiovascular Research, Executive Vice President of Institute of Clinical and Translational Research/Jiangsu Province Hospital, and a co-founder of SyMap Medical Ltd (Approved for “Fast Track” by CFDA; invested by Sequoia and Softbank).
He has published more than 90 peer-reviewed articles, over 100 abstracts and holds more than 40 patents, obtained many grants and rewards.
He has both clinical degree and research degree (New York Medical College). He completed fellowship training at Duke and Harvard University.